05-11-2024 |
PM |
|
CRSP |
CRISPR Therapeutics AG |
3,950 |
-1.01 |
-1.33 |
-1.41 |
CRISPR Therapeutics GAAP EPS of -$1.01 beats by $0.37 [11/5/2024 9:05 AM] |
50.31 |
-0.28 (-0.55%) |
49.36 |
-1.23 (-2.43%) |
43.42 - 91.10 |
1,921,084 |
1,410,000 |
20,749 |
|
|
08-05-2024 |
AH |
|
CRSP |
CRISPR Therapeutics |
4,843 |
-1.43 |
-1.63 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$1.43 misses by $0.03, revenue of $0.5M misses by $24.67M [5/8/2024 4:57 PM] |
53.63 |
0.34 (0.64%) |
52.68 |
-0.61 (-1.14%) |
37.55 - 91.10 |
1,501,074 |
1,340,000 |
17,143 |
|
|
21-02-2024 |
PM |
|
CRSP |
CRISPR Therapeutics AG |
6,710 |
1.10 |
-0.40 |
-1.41 |
CRISPR Therapeutics GAAP EPS of $1.10 beats by $1.33 [2/21/2024 7:44 AM] |
82.19 |
3.46 (4.39%) |
82.47 |
3.74 (4.75%) |
37.55 - 90.18 |
2,792,751 |
2,820,000 |
153,634 |
|
|
06-11-2023 |
AH |
|
CRSP |
CRISPR Therapeutics |
3,667 |
-1.41 |
-1.98 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$1.41 beats by $0.57 [11/6/2023 5:23 PM] |
58.60 |
7.02 (13.61%) |
52.25 |
0.67 (1.30%) |
37.55 - 72.00 |
3,496,321 |
2,420,000 |
40,883 |
|
|
07-08-2023 |
AH |
|
CRSP |
CRISPR Therapeutics |
4,053 |
-0.98 |
-2.18 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$0.98 beats by $1.12, revenue of $70M [8/7/2023 4:55 PM] |
53.09 |
4.75 (9.83%) |
49.05 |
0.71 (1.47%) |
38.94 - 84.10 |
2,184,887 |
1,070,000 |
11,963 |
|
|
01-11-2022 |
AH |
After the close (Nov 1) |
CRSP |
CRISPR Therapeutics |
4,235 |
-2.24 |
-2.30 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$2.24 beats by $0.02, revenue of $0.09M misses by $1.77M [11/1/2022 5:09 PM] |
54.69 |
2.67 (5.13%) |
54.44 |
2.42 (4.65%) |
42.51 - 98.58 |
1,318,671 |
1,010,000 |
797 |
|
|
08-08-2022 |
PM |
Before the open (Aug 8) |
CRSP |
CRISPR Therapeutics |
6,112 |
-2.40 |
-2.23 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M [8/8/2022 8:27 AM] |
81.36 |
-0.04 (-0.04%) |
80.07 |
-1.33 (-1.63%) |
42.51 - 142.64 |
1,399,691 |
1,200,000 |
7,791 |
|
|
09-05-2022 |
AH |
4:00 PM ET (May 9) |
CRSP |
CRISPR Therapeutics |
3,974 |
-2.32 |
-1.91 |
0.00 |
CRISPR Therapeutics GAAP EPS of -$2.32 misses by $0.38, revenue of $0.94M misses by $1.51M [5/9/2022 5:22 PM] |
47.32 |
4.09 (9.46%) |
44.63 |
1.40 (3.24%) |
43.05 - 169.76 |
2,172,209 |
1,380,000 |
6,963 |
|
|
29-07-2021 |
AH |
4:00 PM ET (Jul 29) |
CRSP |
Crispr Therapeutics Ag |
8,898 |
9.44 |
4.19 |
0.00 |
CRISPR Therapeutics EPS beats by $5.59, beats on revenue [7/29/2021 4:59 PM] |
120.90 |
1.90 (1.60%) |
123.30 |
4.30 (3.61%) |
76.71 - 220.20 |
1,313,671 |
1,090,000 |
23,997 |
|
|
27-04-2021 |
AH |
4:00 PM ET (Apr 27) |
CRSP |
CRISPR Therapeutics AG |
9,510 |
-1.51 |
-1.45 |
-1.15 |
CRISPR Therapeutics EPS misses by $0.04, misses on revenue [4/27/2021 4:45 PM] |
135.42 |
2.38 (1.79%) |
132.00 |
-1.04 (-0.78%) |
46.84 - 220.20 |
1,183,396 |
1,720,000 |
11,179 |
|
|
16-02-2021 |
AH |
After the close (Feb 16) |
CRSP |
Crispr Therapeutics Ag |
11,468 |
-1.50 |
-1.23 |
0.00 |
CRISPR Therapeutics EPS misses by $0.23, misses on revenue [2/16/2021 4:18 PM] |
149.73 |
-5.59 (-3.60%) |
150.00 |
-5.32 (-3.43%) |
32.30 - 220.20 |
3,174,236 |
2,483,346 |
45,052 |
|
|
16-02-2021 |
AH |
After the close (Feb 16) |
CRSP |
CRISPR Therapeutics AG |
12,100 |
-1.50 |
-1.23 |
0.51 |
CRISPR Therapeutics EPS misses by $0.23, misses on revenue [2/16/2021 4:18 PM] |
149.73 |
-5.59 (-3.60%) |
150.00 |
-5.32 (-3.43%) |
32.30 - 220.20 |
3,174,236 |
2,483,346 |
45,052 |
|
|